Cleared Traditional

K771606 - IMMUNOSPOT NEONATAL T4 TEST

K771606 is an FDA 510(k) clearance for IMMUNOSPOT NEONATAL T4 TEST, manufactured by Meloy Laboratories, Inc.. The device is a Class 2 Chemistry device with product code CDX cleared through the Traditional 510(k) pathway after a 24-day FDA review.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 1977
Decision
24d
Days
Class 2
Risk

K771606 is an FDA 510(k) clearance for the IMMUNOSPOT NEONATAL T4 TEST. Classified as Radioimmunoassay, Total Thyroxine (product code CDX), Class II - Special Controls.

Submitted by Meloy Laboratories, Inc. (Mchenry, US). The FDA issued a Cleared decision on September 15, 1977 after a review of 24 days - a notably fast clearance cycle.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1700 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

FDA 510(k) Submission Details - K771606

510(k) Number K771606 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 22, 1977
Decision Date September 15, 1977
Days to Decision 24 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
65d faster than avg
Panel avg: 89d · This submission: 24d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

CDX Device Classification - Class 2, Special Controls

Product Code CDX Radioimmunoassay, Total Thyroxine
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.1700
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - CDX Radioimmunoassay, Total Thyroxine

All 120
Devices cleared under the same product code (CDX) and FDA review panel - the closest regulatory comparables to K771606.
THYRODOT-4 ANTISERA LYOPHOLIZED
K772064 · Medcom Diagnostics, Inc. · Nov 1977
AMES T-4 STRIP TEST
K772014 · Miles Laboratories, Inc. · Nov 1977
T4 BY RIA DIAG. KIT
K771414 · Biomedical Labs., Inc. · Sep 1977
T4 RIA TEST SYSTEM
K771221 · Monobind · Aug 1977
RIA FOR TOTAL THYROXINE
K771309 · Abbott Laboratories · Aug 1977
QUANTIMUNE NEONATAL & THYROXINE RIA
K771135 · Bio-Rad · Jul 1977